A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
A Large-Sample Real-World Dynamic Cohort Registry: Observing the Clinical Outcomes of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Zhuhai Trinomab Pharmaceutical Co., Ltd.
10,000 participants
Jul 31, 2025
OBSERVATIONAL
Conditions
Summary
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Eligibility
Inclusion Criteria2
- Having received or will receive Siltartoxatug for tetanus prophylaxis following injury;
- \. Provided signed informed consent by themselves or their legal representatives.
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07107932